163 related articles for article (PubMed ID: 28920711)
21. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
Graf LL; Welsh CH; Qamar Z; Marlar RA
Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
[TBL] [Abstract][Full Text] [Related]
22. A Genetic Origin? Purpura Fulminans.
Avnery O; Kenet G; Ellis MH
Am J Med; 2019 Mar; 132(3):327-328. PubMed ID: 30367859
[No Abstract] [Full Text] [Related]
23. Comparison of Phenotypic Activated Protein C Resistance Testing With a Genetic Assay for Factor V Leiden.
Murphy CH; Sabath DE
Am J Clin Pathol; 2019 Feb; 151(3):302-305. PubMed ID: 30423028
[TBL] [Abstract][Full Text] [Related]
24. Factor V Leiden as a common genetic risk factor for venous thromboembolism.
Horne MK; McCloskey DJ
J Nurs Scholarsh; 2006; 38(1):19-25. PubMed ID: 16579319
[TBL] [Abstract][Full Text] [Related]
25. The effect of lupus anticoagulant in the second-generation assay for activated protein C resistance.
Ragland BD; Reed CE; Eiland BM; Tichenor PH; Hudson CL; Fritsma GA; Adler BK; Marques MB
Am J Clin Pathol; 2003 Jan; 119(1):66-71. PubMed ID: 12520699
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of activated protein C resistance (Factor V Leiden) in Lagos, Nigeria.
Adeyemo TA; Adediran A; Akinbami AA; Akanmu AS
Niger J Clin Pract; 2012; 15(2):136-41. PubMed ID: 22718159
[TBL] [Abstract][Full Text] [Related]
27. Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer.
Paspatis GA; Sfyridaki A; Papanikolaou N; Triantafyllou K; Livadiotaki A; Kapsoritakis A; Lydataki N
Pathophysiol Haemost Thromb; 2002; 32(1):2-7. PubMed ID: 12214157
[TBL] [Abstract][Full Text] [Related]
28. Screening for activated protein C resistance before oral contraceptive treatment: a pilot study.
Palareti G; Legnani C; Frascaro M; Flamigni C; Gammi L; Gola G; Fuschini G; Coccheri S
Contraception; 1999 May; 59(5):293-9. PubMed ID: 10494482
[TBL] [Abstract][Full Text] [Related]
29. [Analysis of activated protein C resistance, factor V coagulation activity and gene polymorphisms in patients with venous thromboembolism].
Han XM; Ren JF; Hao B; Cao WD; Liu XE; Hou LH; Guo ZP; Yu B; Wang XF; Ding QL; Yang LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):612-6. PubMed ID: 17605877
[TBL] [Abstract][Full Text] [Related]
30. Resistance to activated protein C--frequent etiologic factor for venous thrombosis.
Simkova M; Simko F; Kovacs L
Bratisl Lek Listy; 2001; 102(5):240-7. PubMed ID: 11725376
[TBL] [Abstract][Full Text] [Related]
31. Normal functional protein S activity does not exclude protein S deficiency.
Rodger MA; Carrier M; Gervais M; Rock G
Pathophysiol Haemost Thromb; 2003 Jul-2004 Aug; 33(4):202-5. PubMed ID: 15583450
[TBL] [Abstract][Full Text] [Related]
32. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
Favaloro EJ; Bonar R; Sioufi J; Wheeler M; Low J; Aboud M; Duncan E; Smith J; Exner T; Lloyd J; Marsden K;
Semin Thromb Hemost; 2005 Feb; 31(1):49-58. PubMed ID: 15706475
[TBL] [Abstract][Full Text] [Related]
33. Congenital resistance to activated protein C in patients with lupus anticoagulants: evaluation of two functional assays.
Galli M; Duca F; Ruggeri L; Finazzi G; Negri B; Moia M
Thromb Haemost; 1998 Aug; 80(2):246-9. PubMed ID: 9716147
[TBL] [Abstract][Full Text] [Related]
34. [Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis].
Jastrzebska M; Bałszan-Kowalska I; Ciechanowicz A; Bińczak-Kuleta A; Falkowski A; Chełstowski K
Pol Arch Med Wewn; 2003 Jun; 109(6):579-88. PubMed ID: 14567090
[TBL] [Abstract][Full Text] [Related]
35. Interference of factor V Leiden on protein S activity: evaluation of a new prothrombin time-based assay.
Tripodi A; Asti D; Chantarangkul V; Biguzzi E; Mannucci PM
Blood Coagul Fibrinolysis; 2007 Sep; 18(6):543-6. PubMed ID: 17762529
[TBL] [Abstract][Full Text] [Related]
36. Laboratory Testing for Activated Protein C Resistance (APCR): An Update.
Favaloro EJ; Mohammed S; Vong R; Pasalic L
Methods Mol Biol; 2023; 2663():203-210. PubMed ID: 37204711
[TBL] [Abstract][Full Text] [Related]
37. Low cut-off values increase diagnostic performance of protein S assays.
Mulder R; Ten Kate MK; Kluin-Nelemans HC; Mulder AB
Thromb Haemost; 2010 Sep; 104(3):618-25. PubMed ID: 20539904
[TBL] [Abstract][Full Text] [Related]
38. Laboratory Testing for Activated Protein C Resistance (APCR).
Mohammed S; Favaloro EJ
Methods Mol Biol; 2017; 1646():137-143. PubMed ID: 28804824
[TBL] [Abstract][Full Text] [Related]
39. Detection of protein S deficiency: a new functional assay compared to an antigenic technique.
Moraes C; Lofthouse E; Eikelboom J; Thom J; Baker R
Pathology; 2000 May; 32(2):94-7. PubMed ID: 10840827
[TBL] [Abstract][Full Text] [Related]
40. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus.
Dizon-Townson D; Miller C; Sibai B; Spong CY; Thom E; Wendel G; Wenstrom K; Samuels P; Cotroneo MA; Moawad A; Sorokin Y; Meis P; Miodovnik M; O'Sullivan MJ; Conway D; Wapner RJ; Gabbe SG;
Obstet Gynecol; 2005 Sep; 106(3):517-24. PubMed ID: 16135581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
